Burton L Eisenberg

Summary

Affiliation: Dartmouth Medical School
Country: USA

Publications

  1. doi request reprint The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors
    Burton L Eisenberg
    Department of Surgery, Section of Surgical Oncology, Geisel School of Medicine at Dartmouth Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Am J Clin Oncol 36:89-90. 2013
  2. doi request reprint Gastrointestinal stromal tumor--background, pathology, treatment
    Burton L Eisenberg
    Surgical Oncology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Hematol Oncol Clin North Am 26:1239-59. 2012
  3. ncbi request reprint Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials
    Burton L Eisenberg
    Department of Surgery, Surgical Oncology, Darthmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, USA
    Clin Colorectal Cancer 6:S24-9. 2006
  4. doi request reprint Adjuvant and neoadjuvant therapy for primary GIST
    Burton L Eisenberg
    Dartmouth Hitchcock Medical Center and Dartmouth Medical School, Section of Surgical Oncology, Lebanon, NH, USA
    Cancer Chemother Pharmacol 67:S3-8. 2011
  5. pmc Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665
    Burton L Eisenberg
    Section of Surgical Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    J Surg Oncol 99:42-7. 2009
  6. ncbi request reprint Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy
    Burton L Eisenberg
    Section of Surgical Oncology, Norris Cotton Cancer Center, Rubin Building, 8th Floor, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
    Ann Surg Oncol 11:465-75. 2004
  7. pmc A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue
    Margit M McGowan
    Section of Hematology Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center, and Norris Cotton Cancer Center, The Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA
    Breast Cancer Res Treat 138:175-83. 2013
  8. doi request reprint Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors
    Burton L Eisenberg
    Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, NH, USA
    Int J Cancer 129:2533-42. 2011
  9. pmc Lipoprotein lipase links dietary fat to solid tumor cell proliferation
    Nancy B Kuemmerle
    Section of Hematology and Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
    Mol Cancer Ther 10:427-36. 2011
  10. pmc Fatty acid synthesis is a therapeutic target in human liposarcoma
    Arne M Olsen
    Department of Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    Int J Oncol 36:1309-14. 2010

Collaborators

Detail Information

Publications23

  1. doi request reprint The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors
    Burton L Eisenberg
    Department of Surgery, Section of Surgical Oncology, Geisel School of Medicine at Dartmouth Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Am J Clin Oncol 36:89-90. 2013
    ..1 year of adjuvant IM has established a benefit of RFS and OS for the 3 year cohort. Future studies are necessary to continue to further delineate risk variables for GIST recurrence...
  2. doi request reprint Gastrointestinal stromal tumor--background, pathology, treatment
    Burton L Eisenberg
    Surgical Oncology, Geisel School of Medicine at Dartmouth, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    Hematol Oncol Clin North Am 26:1239-59. 2012
    ..The success of molecular targeted therapy in GIST represents an important and exciting advance in solid tumor oncology...
  3. ncbi request reprint Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials
    Burton L Eisenberg
    Department of Surgery, Surgical Oncology, Darthmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, USA
    Clin Colorectal Cancer 6:S24-9. 2006
    ..The results of these studies will be meaningful in future standard therapy consideration...
  4. doi request reprint Adjuvant and neoadjuvant therapy for primary GIST
    Burton L Eisenberg
    Dartmouth Hitchcock Medical Center and Dartmouth Medical School, Section of Surgical Oncology, Lebanon, NH, USA
    Cancer Chemother Pharmacol 67:S3-8. 2011
    ..Advantages can include tumor downsizing to provide opportunity for less morbid surgical resection as well as to decrease risk of intra-op tumor rupture. These theoretical considerations have not been evaluated in large clinical studies...
  5. pmc Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665
    Burton L Eisenberg
    Section of Surgical Oncology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    J Surg Oncol 99:42-7. 2009
    ..There have been no prospective studies either evaluating the neoadjuvant use of IM in primary GIST or as a preoperative cytoreduction agent for metastatic GIST...
  6. ncbi request reprint Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy
    Burton L Eisenberg
    Section of Surgical Oncology, Norris Cotton Cancer Center, Rubin Building, 8th Floor, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
    Ann Surg Oncol 11:465-75. 2004
    ..g., rendering initially inoperable tumors resectable) in the overall management approach to advanced GIST may contribute to surgeons' success in attaining this objective...
  7. pmc A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue
    Margit M McGowan
    Section of Hematology Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center, and Norris Cotton Cancer Center, The Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA
    Breast Cancer Res Treat 138:175-83. 2013
    ..CLA consumption was well-tolerated and safe at this dose for up to 20 days. Overall, CLA may be a prototype compound to target fatty acid synthesis in breast cancers with a "lipogenic phenotype"...
  8. doi request reprint Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors
    Burton L Eisenberg
    Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, NH, USA
    Int J Cancer 129:2533-42. 2011
    ..This article reviews pivotal efficacy and safety data for adjuvant imatinib and explores the potential clinical benefit of neoadjuvant imatinib in patients with GIST...
  9. pmc Lipoprotein lipase links dietary fat to solid tumor cell proliferation
    Nancy B Kuemmerle
    Section of Hematology and Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA
    Mol Cancer Ther 10:427-36. 2011
    ..Interfering with dietary fat intake, lipolysis, and/or FA uptake will be necessary to target the requirement of cancer cells for FA...
  10. pmc Fatty acid synthesis is a therapeutic target in human liposarcoma
    Arne M Olsen
    Department of Surgery, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
    Int J Oncol 36:1309-14. 2010
    ..These findings warrant further studies aimed at the clinical exploitation of the dependence of LS cell growth on fatty acids...
  11. ncbi request reprint Is reporting of recurrence data important in pancreatic cancer?
    Michael O Meyers
    Department of Surgery, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Ann Surg Oncol 11:304-9. 2004
    ..The purpose of this study was to identify patients with recurrent pancreatic cancer and to determine whether treatment after recurrence had any effect on outcome...
  12. ncbi request reprint Combined-modality strategy for gastrointestinal stromal tumors
    Burton L Eisenberg
    Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    Semin Oncol 33:S75-8. 2006
    ..The continued study of combining surgery and a target-specific agent for malignant GIST will be a valuable reference for future strategies combining surgery and targeted treatment in other solid tumors...
  13. pmc Conjugated linoleic acid (CLA) inhibits expression of the Spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cells
    Christina Donnelly
    Department of Medicine, Section of Endocrinology and Metabolism, and the Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire, USA
    Nutr Cancer 61:114-22. 2009
    ..Rescue from the antiproliferative effect of CLA by palmitic acid indicates that reduced tumor lipogenesis is a major mechanism for the anticancer effects of CLA...
  14. ncbi request reprint The association of cytokeratin-only-positive sentinel lymph nodes and subsequent metastases in breast cancer
    Philip S Mullenix
    Department of Surgery, Madigan Army Medical Center, 9040A Reid Street, Tacoma, WA 98431, USA
    Am J Surg 189:606-9; discussion 609. 2005
    ..The purpose of this study was to better characterize the clinical significance of cytokeratin immunohistochemistry (IHC)-only-positive lymph node metastases among patients with breast cancer...
  15. ncbi request reprint Pharmacotherapy of gastrointestinal stromal tumours
    Burton L Eisenberg
    Department of Surgical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Expert Opin Pharmacother 4:869-74. 2003
    ..These initial evaluations with imatinib mesylate provide proof of concept for hypothesis driven, rational drug design of selective signal transduction inhibitors in the management of solid tumour malignancies...
  16. ncbi request reprint Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors
    Burton L Eisenberg
    Department of Surgical Oncology, Fox Chase Cancer Center, Temple University, School of Medicine, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 17:1615-20; discussion 1620, 1623, 1626 passim. 2003
    ..The initial evaluations of imatinib provide proof of concept for the hypothesis-driven design of selective molecularly targeted therapies for solid tumor malignancies...
  17. ncbi request reprint En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?
    Aaron R Sasson
    Department of Surgical Oncology, Temple University School of Medicine, Philadelphia, PA 19111, USA
    J Gastrointest Surg 6:147-57; discussion 157-8. 2002
    ....
  18. ncbi request reprint Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
    Michael C Heinrich
    Division of Hematology Oncology, Department of Pathology, Oregon Health and Science University Cancer Institute, Oregon Health and Science University, Portland, OR, USA
    J Clin Oncol 24:4764-74. 2006
    ..In clinical studies, 75% to 90% of patients with advanced GISTs experience clinical benefit from imatinib. However, imatinib resistance is an increasing clinical problem...
  19. ncbi request reprint Intraoperative radiotherapy in the multimodality approach to bone and soft tissue cancers
    Rodney J Ellis
    Department of Radiation Oncology, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106 6068, USA
    Surg Oncol Clin N Am 12:1015-29. 2003
    ..As IORT use becomes more common, special care will be required to ensure that it is used by a multidisciplinary team of radiation oncologists and surgeons to ensure the best results for patients...
  20. ncbi request reprint Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology
    Robert F Ozols
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 25:146-62. 2007
    ..This report demonstrates the essential role of clinical cancer research in finding new and better ways to treat, diagnose, and prevent a group of diseases that strike half of men and one-third of women in the United States...
  21. ncbi request reprint Soft tissue sarcomas of adults: state of the translational science
    Ernest C Borden
    The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, USA
    Clin Cancer Res 9:1941-56. 2003
    ..Finally, multicenter, coordinated trials, such as those that occurred with assessment of imatinib mesylate in metastatic gastrointestinal stromal tumors, will assure the most rapid reductions in morbidity and mortality...
  22. ncbi request reprint Epidemiology of GIST
    Charles Blanke
    Am J Gastroenterol 100:2366. 2005
  23. ncbi request reprint Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome
    Aaron R Sasson
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Gastrointest Cancer 34:121-8. 2003
    ..Although retrospective,this series suggests an improvement in survival in patients treated with neoadjuvant therapy...